Ipsen and new biotech startup announce oncology partnership

9 March 2016

French drugmaker Ipsen (Euronext: IPN) and new startup PeptiMimesis have announced a new partnership to develop a novel generation of therapeutic peptides targeting membrane receptors which are overexpressed in a large number of cancers.

Only last month PeptiMimesis formally launched its activities to develop the new therapeutic peptides using a breakthrough technology from the University of Strasbourg and INSERM (the French Institute of Health and Medical Research).

Now it has agreed a research deal with Ipsen and a licensing option allowing the company to develop and market new drug candidates which come from the partnership.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK